| 1/20/2022 |
MarketsandMarkets analysis says that a Potential Opportunity Worth $50 Bn is opening up in Genomics |
PRSync |
... advanced genetic sequencing is expected to drive better clinical decision-making in the coming years, presenting lucrative growth opportunities to NGS companies. Additionally, the life sciences market is witnessing an increased adoption of AI, personalized healthcare , gene editing, etc., which is likely to disrupt the demand for genomics, in turn impacting the growth of the market. The increasing demand for sequencing and bioinformatics in diagnostics is predicted to disrupt the ... |
| 1/19/2022 |
Personalizing Patient Engagement: Redox and PatientBond Partner to Bring Consumer Science into Healthcare |
PR Newswire |
... company accelerating interoperability in healthcare, has announced its partnership with PatientBond , the patient engagement platform that employs consumer science to enhance the patient experience. Together PatientBond and Redox will support the seamless integration of personalized healthcare content across any electronic health record (EHR). Providers can now offer a patient engagement experience that leverages retail industry methods to automate dynamic, multi-channel, digital workflows that motivate desired patient behaviors.Although individual ... |
| 1/19/2022 |
Personalizing Patient Engagement: Redox and PatientBond Partner to Bring Consumer Science into Healthcare |
tncontentexchange.com |
... company accelerating interoperability in healthcare, has announced its partnership with PatientBond , the patient engagement platform that employs consumer science to enhance the patient experience. Together PatientBond and Redox will support the seamless integration of personalized healthcare content across any electronic health record (EHR). Providers can now offer a patient engagement experience that leverages retail industry methods to automate dynamic, multi-channel, digital workflows that motivate desired patient behaviors.Although individual ... |
| 1/13/2022 |
Global Real-World Evidence (RWE) Solutions Market Report 2021: Market is Expected to Grow at a CAGR of 11.8% to 2028 to Reach $4.4 Billion |
Globe Newswire |
... to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to ... |
| 1/13/2022 |
Sandra Fenwick Joins Patient Discovery's Board of Directors |
PR Newswire |
... our mission to transform the way all patients are understood, supported and treated through the power of technology.""Patient Discovery is breaking down the barriers for patients from all socio-economic backgrounds to access personalized healthcare ," said Sandi Fenwick . "I'm thrilled to be joining forces with Patient Discovery, and to be at the forefront of improving lives through using real-world, patient data to help solve some of the most ... |
| 1/11/2022 |
Freenome Nets $290M Investment from Roche | 360Dx |
360dx.com |
... to test for additional cancers, and expand our real-world data programs," Freenome CEO Mike Nolan said in a statement."We believe blood-based multimodal screening and data-driven medical insights will help deliver personalized healthcare . This investment will be an important step to advance early cancer screening, and we look forward to joining Freenome in this journey," added Roche Diagnostics CEO Thomas Schinecker ... |
| 1/11/2022 |
Freenome Nets $290M Investment from Roche | Genomeweb |
genomeweb.com |
... to test for additional cancers, and expand our real-world data programs," Freenome CEO Mike Nolan said in a statement."We believe blood-based multimodal screening and data-driven medical insights will help deliver personalized healthcare . This investment will be an important step to advance early cancer screening, and we look forward to joining Freenome in this journey," added Roche Diagnostics CEO Thomas Schinecker ... |
| 1/11/2022 |
Global Real-World Evidence (RWE) Solutions Markets, 2021-2028 - Rising Number of Consolidations & Growing Adoption of RWE in Drug Development and Commercialization |
PR Newswire |
... to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028 Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to ... |
| 1/11/2022 |
Global Real-World Evidence (RWE) Solutions Markets, 2021-2028 - Rising Number of Consolidations & Growing Adoption of RWE in Drug Development and Commercialization |
Yahoo News |
... to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to ... |
| 1/11/2022 |
Global Real-World Evidence (RWE) Solutions Markets, 2021-2028 - Focus on Market Access, Oncology, Neurology, Post Market Surveillance in Pharma Companies & Providers - ResearchAndMarkets.com |
Yahoo News |
... to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to ... |
| 1/11/2022 |
Global Real-World Evidence (RWE) Solutions Markets, 2021-2028 - Focus on Market Access, Oncology, Neurology, Post Market Surveillance in Pharma Companies & Providers - ResearchAndMarkets.com | Business Wire |
Business Wire |
... to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to ... |
| 1/11/2022 |
Global Real-World Evidence (RWE) Solutions Markets, 2021-2028 - Focus on Market Access, Oncology, Neurology, Post Market Surveillance in Pharma Companies & Providers - ResearchAndMarkets.com |
Business Wire |
... to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus towards personalized healthcare are the key factors driving the growth of the global RWE solutions market. Further, significant growth opportunities for existing market players and new entrants are provided by emerging markets, rising focus on end-to ... |
| 1/11/2022 |
Affiliate Event (HBSASC): The Future of Healthcare |
mit.edu |
... of innovation-driven industry and social change across healthcare and technology. In "You and AI", he explores how exponential technologies can solve the problems that plague the American healthcare industry and provide everyone better, personalized healthcare at lower cost. Enterprising healthcare companies are forging the way by integrating exponential technologies right into the company DNA, creating AI-first, blockchain-first, data-first, technology-first digital enterprises for the twenty-first ... |
| 1/11/2022 |
PreciseDx Raises $10.75M in Series A Round | 360Dx |
360dx.com |
... risk for disease progression and recurrence, and recommendations for patient management.The New York City-based company currently offers breast cancer diagnostic test services and has a prostate cancer test in development."AI-enabled, personalized healthcare is the future," David Rubin, managing director of Merck Global Health Innovation Fund, said in a statement. "We believe the ability to create and leverage billions of novel data points has the potential to ... |
| 1/11/2022 |
PCR vs. antigent testing: what's the difference? |
manisteenews.com |
... chain reaction) and antigen tests \u2014 both of which typically use nasal swabs to collect samples \u2014 differ in detection methods, processing, and turnaround times,\u201d says Dr. Ariella Morrow from Sameday Health, a personalized healthcare provider with nationwide covid-testing clinic and services. : We\u2019ve spoken to her and other medical experts about the differences between a PCR and RAT\u2014as well as what situations you should use either ... |
| 1/11/2022 |
PCR vs. antigent testing: what's the difference? |
mysanantonio.com |
... chain reaction) and antigen tests — both of which typically use nasal swabs to collect samples — differ in detection methods, processing, and turnaround times,” says Dr. Ariella Morrow from Sameday Health, a personalized healthcare provider with nationwide covid-testing clinic and services. :We’ve spoken to her and other medical experts about the differences between a PCR and RAT—as well as what situations you should use either ... |
| 1/11/2022 |
PCR vs. antigent testing: what's the difference? |
Seattle PI |
... chain reaction) and antigen tests — both of which typically use nasal swabs to collect samples — differ in detection methods, processing, and turnaround times,” says Dr. Ariella Morrow from Sameday Health, a personalized healthcare provider with nationwide covid-testing clinic and services. :We’ve spoken to her and other medical experts about the differences between a PCR and RAT—as well as what situations you should use either ... |
| 1/10/2022 |
Accolade Announces Results for Fiscal Third Quarter 2022 |
Yahoo News |
... the fiscal third quarter ended November 30, 2021.“It is remarkable for me to look back at the last twelve months and consider Accolade’s transformation from a navigation and advocacy company to a personalized healthcare company. In January 2021, we were serving about 100 customers and 2 million members. Today, with the integration of primary care, mental health and expert medical opinion from our acquisitions of PlushCare and 2nd.MD ... |
| 1/10/2022 |
Fierce Healthcare names b.well Connected Health as one of its 2022 "Fierce 15" companies |
PR Newswire |
... backers and its innovative approach to solving some of the most complex and longstanding problems in the health industry."b.well is helping health systems, employers and pharmacy chains across the country to deliver the personalized healthcare experience that consumers have been demanding so they can get care when, where and how they want it," said Kristen Valdes , CEO and Founder of b.well. "We are honored to be included in the ... |
| 1/10/2022 |
PCR vs. antigent testing: what's the difference? |
myplainview.com |
... chain reaction) and antigen tests — both of which typically use nasal swabs to collect samples — differ in detection methods, processing, and turnaround times,” says Dr. Ariella Morrow from Sameday Health, a personalized healthcare provider with nationwide covid-testing clinic and services. :We’ve spoken to her and other medical experts about the differences between a PCR and RAT—as well as what situations you should use either ... |